Unity Biotechnology Management
Management criteria checks 3/4
Unity Biotechnology's CEO is Anirvan Ghosh, appointed in Mar 2020, has a tenure of 4.75 years. total yearly compensation is $1.26M, comprised of 48.3% salary and 51.7% bonuses, including company stock and options. directly owns 0.44% of the company’s shares, worth $70.58K. The average tenure of the management team and the board of directors is 4.5 years and 6.4 years respectively.
Key information
Anirvan Ghosh
Chief executive officer
US$1.3m
Total compensation
| CEO salary percentage | 48.3% |
| CEO tenure | 4.8yrs |
| CEO ownership | 0.4% |
| Management average tenure | 4.5yrs |
| Board average tenure | 6.4yrs |
Recent management updates
Recent updates
Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth?
Nov 05
Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?
Jul 12Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation
Mar 05Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky
Nov 18UNITY Biotechnology falls 7% on reverse stock split
Oct 19Unity Biotechnology cuts stock sales agreement in half to $25M
Aug 19Unity Biotechnology GAAP EPS of -$0.19 beats by $0.10, revenue of $0.24M
Aug 12A Look At Unity's UBX1325 Phase 1 Results
Jul 26Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently
Dec 22A Look Inside Unity Bio's Transition To An Ophthalmology Company
Nov 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$22m |
| Jun 30 2024 | n/a | n/a | -US$30m |
| Mar 31 2024 | n/a | n/a | -US$40m |
| Dec 31 2023 | US$1m | US$609k | -US$40m |
| Sep 30 2023 | n/a | n/a | -US$34m |
| Jun 30 2023 | n/a | n/a | -US$33m |
| Mar 31 2023 | n/a | n/a | -US$31m |
| Dec 31 2022 | US$2m | US$580k | -US$44m |
| Sep 30 2022 | n/a | n/a | -US$56m |
| Jun 30 2022 | n/a | n/a | -US$59m |
| Mar 31 2022 | n/a | n/a | -US$64m |
| Dec 31 2021 | US$4m | US$562k | -US$61m |
| Sep 30 2021 | n/a | n/a | -US$70m |
| Jun 30 2021 | n/a | n/a | -US$81m |
| Mar 31 2021 | n/a | n/a | -US$82m |
| Dec 31 2020 | US$7m | US$417k | -US$94m |
Compensation vs Market: Anirvan's total compensation ($USD1.26M) is above average for companies of similar size in the US market ($USD653.16K).
Compensation vs Earnings: Anirvan's compensation has been consistent with company performance over the past year.
CEO
Anirvan Ghosh (60 yo)
4.8yrs
Tenure
US$1,260,838
Compensation
Dr. Anirvan Ghosh, Ph D., serves as Chief Executive Officer and Director of Unity Biotechnology, Inc. since March 30, 2020. Dr. Ghosh had been Senior Vice President, Head of Research and Early Development...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.8yrs | US$1.26m | 0.44% $ 70.6k | |
| Co-Founder & Executive Director | 13.9yrs | US$55.20k | 0.35% $ 56.6k | |
| CFO & Head of Corporate Development | 4.3yrs | US$771.59k | 0.33% $ 52.9k | |
| Chief Legal Officer | 3.8yrs | US$677.80k | 0.024% $ 3.8k | |
| Founder | 13.9yrs | no data | no data | |
| Founder | 13.9yrs | no data | no data | |
| Chief Scientist | 3.8yrs | no data | no data | |
| Chief Strategy Officer | less than a year | no data | no data |
4.5yrs
Average Tenure
57yo
Average Age
Experienced Management: UBX's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.8yrs | US$1.26m | 0.44% $ 70.6k | |
| Co-Founder & Executive Director | 13.1yrs | US$55.20k | 0.35% $ 56.6k | |
| Independent Director | 9.8yrs | US$65.70k | 0.0060% $ 975.2 | |
| Lead Independent Director | 6.8yrs | US$92.70k | 0.0019% $ 312.1 | |
| Chairman | 8.9yrs | US$85.20k | 0.13% $ 20.7k | |
| Independent Director | 6yrs | US$59.20k | 0% $ 0 | |
| Independent Director | 2.6yrs | US$70.20k | 0% $ 0 | |
| Independent Director | 4yrs | US$60.20k | 0% $ 0 |
6.4yrs
Average Tenure
58.5yo
Average Age
Experienced Board: UBX's board of directors are considered experienced (6.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 00:09 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Unity Biotechnology, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Elemer Piros | Cantor Fitzgerald & Co. |
| Yigal Nochomovitz | Citigroup Inc |
| Andrew Fein | H.C. Wainwright & Co. |